Odulimomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD11a |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Odulimomab is an investigational drug for the prevention of transplant rejection[1][2] and for the treatment of various immunological diseases.[3][4]
It is a mouse monoclonal antibody directed against the alpha chain of the protein lymphocyte function-associated antigen 1 which is involved in immune reactions.[1]
References
- ^ a b Martin X, Da Silva M, Virieux SR, Hadj Aissa A, Buffet R, Tiollier J, Dubernard JM (March 2000). "Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation". Transplantation Proceedings. 32 (2): 481. doi:10.1016/S0041-1345(00)00849-6. PMID 10715487.
- ^ Crétolle-Vastel C, Camby C, Cerf-Bensussan N, Cavazzana-Calvo M, Fischer A, Révillon Y, Sarnacki S (November 1999). "[Role of calcineurin-dependent drugs on the immunosuppressive effect induced by the anti-LFA-1 antibody in a fetal intestinal transplantation model in mice]". Chirurgie; Mémoires de l'Académie de Chirurgie. 124 (5): 503–10. doi:10.1016/s0001-4001(00)88272-0. PMID 10615777.
- ^ Whitcup SM, Chan CC, Kozhich AT, Magone MT (November 1999). "Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis". Clinical Immunology. 93 (2): 107–13. doi:10.1006/clim.1999.4775. PMID 10527686.
- ^ Corbascio M, Mahanty H, Osterholm C, Qi Z, Pearson TC, Larsen CP, et al. (July 2002). "Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice". Transplantation. 74 (1): 35–41. doi:10.1097/00007890-200207150-00007. PMID 12134096. S2CID 35637410.